🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Vaccine versus antibody cocktail??? VACCINES ANTIBODY 187.2 million 2676 patients 3 deaths. 2 deaths Prevention. Treatment 94 +% efficacy. 70% $. $$$

So folks who refused vaccines (because they were “experimental” and not FDA approved) are suddenly allowing an “experimental” and off-label drug use because they’re sick with COVID? So much for that logic… gene.com/media/statemen…

Just fantastic. Vaccine "hesitancy" is starting to negatively impact cancer patients. Folks won't get vaccinated but they want monoclonals, remdesivir, dex, tocilizumab... the list goes on. Rheum and CAR-T patients are now being put in harms way. #VaccineMandate

We on the CDC ACIP just voted 14 to 0 in favor of Pfizer COVID-19 vaccination for children aged 5 to 11. This helps explain why -

Kudos to Matthew Frigault Impressive data with prodigy based CD37 CAR. Nice to see honest reporting of rescue allo. That should be mandatory for CAR abstracts #lymsm #ASH21

Excited to share our phase I/II of tisagenlecleucel in PCNSL: The Leukemia & Lymphoma Society ASH Mass General Cancer Center - Median # of prior therapies = 4 - ORR 58.3% (7/12) - CR rate 50% (6/12) - Responses seen beyond 12 months - Trafficking to CNS by flow and VCN ashpublications.org/blood/article/…

✨ New today in nature! Dr. Dr Marcela Maus at Harvard Medical School and colleagues demonstrated that liquid 💧 and solid 🧊 tumors differ in their interactions with #CAR T cells, particularly in regards to the IFNγR pathway. go.nature.com/3xr4bfz

Delighted to share our work optimizing CAR-T cells for acute myeloid leukemia. We're working rapidly on this devastating disease and will be presenting our dual targeting strategy building on this publication in May sex in Washington DC Cancer Cell cell.com/cancer-cell/fu…

Two great opening slides by Carl June talking about well recognized “white male” AND under appreciated female pioneers in cell therapy. Including former UC San Francisco co-fellow and labmate Kristen Hege. In ASTCT ASGCT #Tandem22 Joint Seesion.

Phase 1 Study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma #NewCARontheBlock 100% ORR, 75% sCR/CR, 7/12 EM disease, 9/10 with high-risk cytogenetics (2 EM disease only), 10/12 penta-refractory ashpublications.org/bloodadvances/…

Excited to be part of the ddBCMA Phase I and look forward to the pivotal study which should be enrolling later this year! Congrats to my co-investigators and a big thank you to our patients Mass General Cancer Center

#ASCO22 | Abstract Presentation | Sat 3:27pm CDT Single-cell profiling of human heart and blood in immune checkpoint inhibitor-associated myocarditis. Presenter: Steven Michael Blum, MD (Steve Blum) ➡️bit.ly/3mb1Ezw ASCO

Great work by Paul E. Hanna, MD MSc and meg sise. Mass General Cancer Center

Don’t miss the plenary session at #ASCO2022 … transplant significantly better with triplets for #mmsm

So I guess this means they're going to let concealed weapons into the capital and supreme court chambers? Where's the line? theguardian.com/us-news/2022/j…

But if you recount the votes homeopathically Dr Oz won by a landslide

Great data by Matthew Frigault on the successful use of itacitinib for CRS prophylaxis prior to CART for #lymphoma! No safety issues #ASH23

Exciting prelim results from our trial of Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma! Great cross disciplinary collaboration between cell therapy, neuro-onc and neuro-surgery. Mass General Cancer Center Dr Marcela Maus Bryan D. Choi MD PhD!